Evicenter
Nurtec ODT (rimegepant) in Acute treatment of migraine
Manufacturer
Pfizer Inc
Prescribing information
Nurtec ODT (opens in a new tab)
Questions
17
Last updated

All questions

Clinical trials: Nurtec ODT (rimegepant) in acute treatment of migraine

7 questions · 3 sources

Study results

How was Nurtec ODT studied for acute migraine (trial 303)?

Note: The label calls this trial Study 1 (NCT03461757); the Nurtec HCP site calls it trial 303 and cites NCT03461757 for study BHV3000-303.

How many patients were pain free 2 hours after Nurtec ODT vs placebo?

Note: Single 75 mg dose of Nurtec ODT compared with placebo in adults treating a migraine attack of moderate to severe pain (Study 1, NCT03461757). Table 1 columns are NURTEC ODT 75 mg and placebo, in that order. MBS is the most bothersome symptom (photophobia, phonophobia, or nausea).

Does Nurtec ODT relieve migraine pain at 2 hours vs placebo?

Note: Single 75 mg dose of Nurtec ODT compared with placebo in adults treating a migraine attack of moderate to severe pain (Study 1, NCT03461757). Table columns are NURTEC ODT 75 mg and placebo, in that order.

How many patients stayed pain free 2 to 48 hours after Nurtec ODT?

Note: Single 75 mg dose of Nurtec ODT compared with placebo (Study 1, NCT03461757); the row is from Table 2 of the label, whose columns are NURTEC ODT 75 mg and placebo, in that order.

How many patients needed rescue medication within 24 hours after Nurtec ODT?

Note: Single 75 mg dose of Nurtec ODT compared with placebo in trial 303 (the label's Study 1, NCT03461757). The label table gives the percentage who used rescue medication; the HCP page gives the percentage who did not.

How many patients reported normal function 2 hours after Nurtec ODT?

Note: Single 75 mg dose of Nurtec ODT compared with placebo (Study 1, NCT03461757); columns are NURTEC ODT 75 mg and placebo, in that order.

Does Nurtec ODT work when triptans failed or are contraindicated (trial 406)?

Note: Trial 406 compared Nurtec ODT with placebo in adults with a history of treatment failure with 2 or more triptans or a documented contraindication to triptans; the page footnotes refer to rimegepant 75 mg. The page labels pain freedom at 2 hours a select secondary endpoint beside the result and lists pain freedom at 2 hours among the additional secondary endpoints in its endpoint list. The result for the primary endpoint, pain relief at 2 hours, appears on the page only as a graphic and is not quoted. Trial 406 is not described in the Prescribing Information.